Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413316 · ClinicalTrials.gov registry record
ABC-CT Pre-School Feasibility Study
A clinical trial of Autism Spectrum Disorder, sponsored by Yale University.
- Completed
- Registry status
- 50
- Enrollment target
- 5
- Study locations
NCT06413316: Completed study of Autism Spectrum Disorder, sponsored by Yale University.
NCT06413316 is a study of Autism Spectrum Disorder that has completed, run by Yale University. The registered enrollment target is 50 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06413316, a study of Autism Spectrum Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter study that aims to determine whether the EEG and ET experiments studied in the ABC-CT Phase 1 and ABC-CT Confirmation studies can be successfully used with 3-5-year-old children and to determine the viability of these measures as potential biomarkers in 3-5-year-old children with ASD. Blood (DNA) samples will be collected from participants with ASD and biological parents for future genomic analyses, and raw, processed, and analyzed data will be shared to create a community resource accessible for use by all qualified investigators. These objectives are designed to advance the long term objective of developing promising biomarkers via the FDA Biomarker Qualification Program. This feasibility study aims to enroll 25 ASD and 25 TD eligible participants who are 3-5 years old.
Primary Outcome
The N170 Latency to Upright Human Faces (N170 latency) is a scalp recorded EEG event-related potential (ERP) component elicited by perception of the upright human face. Recorded over the posterior-temporal right hemisphere, the latency (or speed) of the peak of the N170 ERP component occurs at approximately 200 msec in children aged 6 to 11 years of age and will be later in 3 to 5 year old children.
Conditions Studied
Study Locations (5)
California
- Children's Hospital Los Angeles - Los Angeles
Connecticut
- Yale Child Study Center - New Haven
Massachusetts
- Boston Children's Hospital - Boston
North Carolina
- Duke University - Durham
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2025-06-30 |
What the finished NCT06413316 record still lists
NCT06413316 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06413316 lists 5 locations in 5 states (California, Connecticut, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06413316 about?
NCT06413316 is a clinical study titled "ABC-CT Pre-School Feasibility Study". This is a multicenter study that aims to determine whether the EEG and ET experiments studied in the ABC-CT Phase 1 and ABC-CT Confirmation studies can be successfully used with 3-5-year-old children and to determine the viability of these measures as potential biomarkers in 3-5-year-old children wi...
What is the current status of trial NCT06413316?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2024-07-02. Estimated completion is 2025-06-30.
What conditions does trial NCT06413316 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
Who is sponsoring clinical trial NCT06413316?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06413316 being conducted?
This trial has 5 study locations across California, Connecticut, Massachusetts, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06413316's enrollment target sits among peer trials
50 141st of 224 higher than 79 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI